Immunomodulator agent-related lymphoproliferative disorders (Q43273894)

18 November 2017

Immunomodulator agent-related lymphoproliferative disorders (English)

1 reference

18 November 2017

4

1 reference

18 November 2017

Robert P Hasserjian

1

1 reference

18 November 2017

Steve Chen

2

1 reference

18 November 2017

Sherrie L Perkins

3

1 reference

18 November 2017

Marsha C Kinney

5

1 reference

18 November 2017

Todd S Barry

6

1 reference

18 November 2017

Jonathan Said

7

1 reference

18 November 2017

Megan S Lim

8

1 reference

18 November 2017

William G Finn

9

1 reference

18 November 2017

L Jeffrey Medeiros

10

1 reference

18 November 2017

Nancy L Harris

11

1 reference

18 November 2017

Dennis P O'Malley

12

1 reference

18 November 2017

18 September 2009

1 reference

18 November 2017

1 reference

18 November 2017

22

1 reference

18 November 2017

12

1 reference

18 November 2017

1532-1540

1 reference

https://scigraph.springernature.com/pub.10.1038/modpathol.2009.131

18 November 2017

0 references

cites work

Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.131

Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.131

Use of biologics in rheumatoid arthritis: where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.131

7 January 2021

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.131

7 January 2021

Spontaneous regression of EBV-associated diffuse lymphoproliferative disease in a patient with rheumatoid arthritis after discontinuation of etanercept treatment.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.131

7 January 2021

A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.131

7 January 2021

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.131

7 January 2021

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.131

7 January 2021

Risk of malignancy among patients with rheumatic conditions

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.131

7 January 2021

Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.131

7 January 2021

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.131

7 January 2021

T-cell clonality determination using polymerase chain reaction (PCR) amplification of the T-cell receptor gamma-chain gene and capillary electrophoresis of fluorescently labeled PCR products

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.131

7 January 2021

Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.131

7 January 2021

Case records of the Massachusetts General Hospital. Case 8-2006. A 71-year-old woman with Crohn's disease and altered mental status

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.131

7 January 2021

Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.131

7 January 2021

Risk of haematopoietic cancer in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.131

7 January 2021

Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.131

7 January 2021

Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.131

7 January 2021

Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.131

7 January 2021

A transient benign lymph node-based proliferation of T-cells simulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor alpha and CD11a antagonists

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.131

7 January 2021

Aggressive cutaneous T-cell lymphomas after TNFalpha blockade

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.131

7 January 2021

10.1038/MODPATHOL.2009.131

Identifiers

DOI

1 reference

Dimensions Publication ID

18 November 2017

0 references

1 reference